SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced that it will present clinical
data from two Phase 1 studies of its norovirus oral tablet vaccine at
the upcoming 18th International Congress on Infectious Diseases (ICID),
taking place from March 1-4, 2018 in Buenos Aires, Argentina.
"The clinical data to be presented at ICID demonstrate that our orally
administered norovirus tablet vaccine was well-tolerated and generated
robust systemic and local intestinal immune responses," said Sean
Tucker, Ph.D., founder and chief scientific officer of Vaxart. "We
believe the quality of the intestinal responses, including both memory
and local effector IgA B-cell responses, is unique to our platform and
could lead to superior efficacy against an enteric pathogen such as
norovirus. Importantly, we did not see any evidence of anti-vector
immunity with our oral vaccine, another unique feature of our platform
and a potential key advantage over injectable vectored vaccines."
Presentation Title: Oral immunization of a rAd vector
expressing norovirus VP1 elicits a potent mucosal immune response
without an increase in anti-vector immunity
Date & Time: Saturday,
March 3, 2018 from 5:00 - 6:00 PM ART
Authors: Sean Tucker,
et al.
Session: Zoonoses
All recent presentations are available on the Vaxart website under
Newsroom at www.vaxart.com.
About Vaxart
Vaxart is a clinical-stage company focused on developing oral
recombinant protein vaccines based on its proprietary oral vaccine
platform and direct-acting antivirals to treat infections that have
limited therapeutic options. Vaxart's oral vaccines are designed to
generate broad and durable immune responses that protect against a wide
range of infectious diseases and may be useful for the treatment of
chronic viral infections and cancer. Vaxart's oral vaccines are
administered using a convenient room temperature-stable tablet, rather
than by injection. Vaxart believes that tablet vaccines are easier to
distribute and administer than injectable vaccines, and have the
potential to significantly increase vaccination rates. Vaxart's
development programs include oral tablet vaccines that are designed to
protect against norovirus, seasonal influenza and respiratory syncytial
virus (RSV), as well as a therapeutic vaccine for human papillomavirus
(HPV). Through the merger, Vaxart also acquired antiviral drug
candidates, including teslexivir (BTA074), an antiviral treatment for
condyloma caused by HPV types 6 and 11. For more information, please
visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, beliefs and expectations
of management are forward-looking statements. These forward-looking
statements may be accompanied by such words as "believe," "could,"
"potential" and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements relating to
Vaxart's ability to develop its pipeline of proprietary oral vaccines
and direct-acting virals, as well as the anticipated timing of value
creating events. Vaxart may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that Vaxart makes, that Vaxart's product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S. regulatory
authorities, Vaxart's product candidates may not achieve broad market
acceptance; and the risks described in the "Risk Factors" sections of
the Registration Statement on Form S-4 (file no. 333-222009) and of
Vaxart's periodic reports filed with the SEC. Vaxart does not assume any
obligation to update any forward-looking statements, except as required
by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180302005118/en/
W2O
Katie Hogan, 415-658-9745
khogan@wcgworld.com
or
Stern
Investor Relations
Carl Mauch, 212-362-1200
vaxart@sternir.com
Source: Vaxart, Inc.
News Provided by Acquire Media